Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad cuts 2024 outlook; Q2 sales fall 6.3% to $638.5 million

Negative Impact 4 of 5 guidance Written later

Bio-Rad reported second-quarter 2024 net sales of $638.5 million, down 6.3% from a year earlier, and a GAAP net loss of $2,165.5 million, driven by a change in the fair market value of its Sartorius AG investment. The company lowered its full-year 2024 outlook, now expecting non-GAAP revenue to decline 2.5% to 4.0% on a currency-neutral basis, and its board raised the buyback authorization by $500 million.

Key points

  • Q2 2024 net sales were $638.5 million, down 6.3% from $681.1 million; Life Science fell 16.5% and Clinical Diagnostics rose 2.1%.
  • GAAP net loss was $2,165.5 million, or $76.26 per diluted share, versus a loss of $39.59 per share a year earlier; non-GAAP EPS was $3.11 versus $3.00.
  • Full-year 2024 non-GAAP revenue outlook moved to a 2.5% to 4.0% decline from prior 1.0% to 2.5% growth; non-GAAP operating margin outlook cut to 12.0% to 13.0% from 13.5% to 14.0%.
  • On July 29, 2024, the board authorized up to an additional $500 million in repurchases; about $578 million was available as of July 31, 2024.

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECAug 1, 2024, 4:18 PM ET
Accession number0000012208-24-000050

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 01, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.